[18F]Florbetaben: A Review in β-Amyloid PET Imaging in Cognitive Impairment
- 375 Downloads
Intravenous 18F-labelled florbetaben ([18F]florbetaben) [Neuraceq™] is a polyethylene glycol stilbene derivative that is approved in the USA, EU and South Korea for positron emission tomography (PET) imaging of the brain. It is used to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive impairment. In vitro, [18F]florbetaben has high affinity and selectivity for β-amyloid. It has a short PET scan time (15–20 min). Visual assessment of regional and whole brain [18F]florbetaben PET images detected brain β-amyloid with high sensitivity and specificity, with good inter-reader agreement, in a phase III study in patients with various levels of cognitive function when compared with postmortem histopathological assessment. The whole brain visual assessment displayed high positive and negative predictive values, enabling amyloid pathology to be reliably detected or excluded. Quantitative PET analyses were generally consistent with the visual assessments. [18F]florbetaben was generally well tolerated in clinical trials. All adverse reactions in [18F]florbetaben recipients were mild to moderate in severity and the most common were injection-site-related (erythema, irritation and pain). There were no serious adverse reactions related to [18F]florbetaben. In summary, [18F]florbetaben is a highly accurate β-amyloid PET tracer that has the potential to support the clinical diagnosis of Alzheimer’s disease and other causes of cognitive decline.
KeywordsPositron Emission Tomography Mild Cognitive Impairment Standardize Uptake Value Positron Emission Tomography Image Dementia With Lewy Body
The preparation of this review was not supported by any external funding. Yahiya Y. Syed and Emma Deeks are salaried employees of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author(s) on the basis of scientific and editorial merit.
- 10.European Medicines Agency. Neuraceq 300 MBq/mL solution for injection: summary of product characteristics. 2014. http://www.ema.europa.eu. Accessed 13 Mar 2015.
- 14.Piramal Imaging. Neuraceq (florbetaben F 18 injection): US prescribing information. 2014. http://www.neuraceq.com. Accessed 13 Mar 2015.
- 17.European Medicines Agency. Neuraceq [florbetaben (18F)]: assessment report for an initial marketing authorisation application. 2013. http://www.ema.europa.eu. Accessed 13 Mar 2015.
- 23.Sabri O, Seibyl J, Ishihara K, et al. Close to clinical routine phase 2 trial on florbetaben PET imaging of β-amyloid (Aβ) in Alzheimer’s disease (AD) [abstract no. 299]. J Nucl Med. 2013;54(Suppl 2).Google Scholar
- 25.US National Institutes of Health. ClinicalTrials.gov. 2014. http://www.clinicaltrials.gov/. Accessed 13 Mar 2015.
- 28.US Food and Drug Administration. Neuraceq (florbetaben F 18 injection): clinical pharmacology and biopharmaceutics review(s). 2014. http://www.fda.gov/. Accessed 13 Mar 2015.
- 29.Sattler B, Barthel H, Patt M, et al. Radiation exposure by [F18]florbetaben, a new PET tracer for detection of cerebral β-amyloid in Caucasian and Asian healthy volunteers [abstract no. OP432]. Eur J Nucl Med Mol Imaging. 2010;37(Suppl 2):S274.Google Scholar
- 32.Seibyl J, Barthel H, Stephens A, et al. Reliability, reproducibility and efficacy of the 18F florbetaben β-amyloid PET scan visual assessment method as trained via a computer-based instructional tool [abstract no. 300]. J Nucl Med. 2013;54(Suppl 2).Google Scholar
- 33.Piramal Imaging SA. Piramal Imaging SA and Ci-Co Healthcare announce commercial approval of Neuraceq™ in Korea [media release]. 2 Jun 2015. http://www.piramal.com.
- 34.Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.PubMedCentralCrossRefPubMedGoogle Scholar
- 35.Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.PubMedCentralCrossRefPubMedGoogle Scholar
- 36.McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.PubMedCentralCrossRefPubMedGoogle Scholar
- 37.American Psychiatric Association. Neurocognitive disorders. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.Google Scholar
- 38.Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9(1):e-1–16.Google Scholar
- 41.Klunk WE, Koeppe RA, Price JC, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1–15 e1–4.Google Scholar
- 42.Data on file, Piramal Imaging. 2015.Google Scholar